YOUR SEARCH FOR Text 261 RESULTS
161 of Total
0000879169-23-000041 | 10-Q | Incyte
Annual Reports Quarterly Reports SEC Filings SEC Filing Details Document Details Form 10-Q Filing Date Oct 31, 2023 Document Date Sep 30, 2023 Form
162 of Total
0000879169-24-000077 | 10-Q | Incyte
Annual Reports Quarterly Reports SEC Filings SEC Filing Details Document Details Form 10-Q Filing Date Apr 30, 2024 Document Date Mar 31, 2024 Form
163 of Total
0000879169-24-000149 | 10-Q | Incyte
Annual Reports Quarterly Reports SEC Filings SEC Filing Details Document Details Form 10-Q Filing Date Jul 30, 2024 Document Date Jun 30, 2024 Form
164 of Total
0000879169-24-000172 | 10-Q | Incyte
Annual Reports Quarterly Reports SEC Filings SEC Filing Details Document Details Form 10-Q Filing Date Oct 29, 2024 Document Date Sep 30, 2024 Form
165 of Total
0000879169-25-000056 | 10-Q | Incyte
Annual Reports Quarterly Reports SEC Filings SEC Filing Details Document Details Form 10-Q Filing Date Apr 29, 2025 Document Date Mar 31, 2025 Form
166 of Total
0000879169-25-000103 | 10-Q | Incyte
Annual Reports Quarterly Reports SEC Filings SEC Filing Details Document Details Form 10-Q Filing Date Jul 29, 2025 Document Date Jun 30, 2025 Form
167 of Total
0000879169-25-000118 | 10-Q | Incyte
Annual Reports Quarterly Reports SEC Filings SEC Filing Details Document Details Form 10-Q Filing Date Oct 28, 2025 Document Date Sep 30, 2025 Form
168 of Total
0000879169-26-000026 | 10-Q | Incyte
Annual Reports Quarterly Reports SEC Filings SEC Filing Details Document Details Form 10-Q Filing Date Apr 28, 2026 Document Date Mar 31, 2026 Form
169 of Total
0000879169-26-000056 | 10-Q | Incyte
Annual Reports Quarterly Reports SEC Filings SEC Filing Details Document Details Form 10-Q Filing Date Jul 28, 2026 Document Date Jun 30, 2026 Form
170 of Total
0001558370-22-006808 | 10-Q | Incyte
Annual Reports Quarterly Reports SEC Filings SEC Filing Details Document Details Form 10-Q Filing Date May 3, 2022 Document Date Mar 31, 2022 Form
A New Frontier
in Hematology
Incyte proudly adds VGA039 and the
VIVID study to its hematology portfolio.